Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
141 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Amyloidosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Amyloidosis - Pipeline Review, H1 2016', provides an overview of the Amyloidosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Amyloidosis - The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects - The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Amyloidosis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Amyloidosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Amyloidosis Overview 10 Therapeutics Development 11 Pipeline Products for Amyloidosis - Overview 11 Pipeline Products for Amyloidosis - Comparative Analysis 12 Amyloidosis - Therapeutics under Development by Companies 13 Amyloidosis - Therapeutics under Investigation by Universities/Institutes 15 Amyloidosis - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Amyloidosis - Products under Development by Companies 19 Amyloidosis - Products under Investigation by Universities/Institutes 21 Amyloidosis - Companies Involved in Therapeutics Development 22 Alnylam Pharmaceuticals, Inc. 22 Arcturus Therapeutics, Inc 23 Bellus Health Inc. 24 Bsim2 25 Celgene Corporation 26 GlaxoSmithKline Plc 27 Neurimmune Holding AG 28 NeuroPhage Pharmaceuticals, Inc. 29 Onyx Pharmaceuticals, Inc. 30 Pfizer Inc. 31 Prothena Corporation Plc 32 SOM Innovation Biotech SL 33 Takeda Pharmaceutical Company Limited 34 Amyloidosis - Therapeutics Assessment 35 Assessment by Monotherapy Products 35 Assessment by Combination Products 36 Assessment by Target 37 Assessment by Mechanism of Action 39 Assessment by Route of Administration 41 Assessment by Molecule Type 43 Drug Profiles 45 ALN-ANG - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 ALN-TTRsc02 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 carfilzomib - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 CLR-01 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 eprodisate disodium - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 GSK-2315698 + GSK-2398852 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 GSK-3039294 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 inotersen sodium - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ixazomib citrate - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 LUNAR-101 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 LUNAR-102 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 LUNAR-TTR - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Monoclonal Antibody for Amyloidosis - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Monoclonal Antibody to Inhibit ATTR for Familial Amyloid Polyneuropathy - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 NEOD-001 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 NI-301 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 NPT-005 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 patisiran - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 pomalidomide - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 PTI-110 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 revusiran - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecules for AL Amyloidosis - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Small Molecules to Inhibit Transthyretin for Familial Amyloid Polyneuropathy - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Cardiomyopathy - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules to Inhibit Transthyretin Related Amyloid Protein for Familial Amyloidotic Polyneuropathy - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 tafamidis meglumine - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 tolcapone - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Amyloidosis - Recent Pipeline Updates 91 Amyloidosis - Dormant Projects 128 Amyloidosis - Product Development Milestones 129 Featured News & Press Releases 129 Feb 09, 2016: Data From Prothena Ongoing Phase 1/2 Clinical Trial of NEOD001 in AL Amyloidosis Published in the Journal of Clinical Oncology 129 Feb 01, 2016: Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 130 Jan 21, 2016: Auven Therapeutics and Bellus Health Announce Completion of Pivotal Phase 3 Confirmatory Trial of KIACTA for the Treatment of Orphan Disease AA Amyloidosis 131 Dec 17, 2015: Isis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase 2 Study of ISIS-TTR Rx in Patients with TTR Cardiomyopathy Amyloidosis 132 Nov 05, 2015: Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting 133 Nov 05, 2015: Prothena to Present New Preclinical Data for NEOD001 at 57th Annual American Society of Hematology Meeting 134 Nov 03, 2015: Isis Pharmaceuticals Reports an Update on ISIS-TTR Rx, Including Positive Data from Multiple Clinical Studies, Presented at the EC-ATTR Meeting 135 Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Patisiran in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 136 Nov 03, 2015: Alnylam Reports Positive Results from Ongoing Phase 2 Open-Label Extension Studies for Revusiran, in Development for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis 137 Oct 27, 2015: Isis Pharmaceuticals to Host Webcast to Review ISIS-TTR Data Presented at 1st European Congress of Hereditary ATTR Amyloidosis and Provide Phase 3 Development Plan Update 139 Appendix 140 Methodology 140 Coverage 140 Secondary Research 140 Primary Research 140 Expert Panel Validation 140 Contact Us 140 Disclaimer 141
List of Tables Number of Products under Development for Amyloidosis, H1 2016 11 Number of Products under Development for Amyloidosis - Comparative Analysis, H1 2016 12 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 15 Comparative Analysis by Late Stage Development, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 17 Comparative Analysis by Early Stage Development, H1 2016 18 Products under Development by Companies, H1 2016 19 Products under Development by Companies, H1 2016 (Contd..1) 20 Products under Investigation by Universities/Institutes, H1 2016 21 Amyloidosis - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 22 Amyloidosis - Pipeline by Arcturus Therapeutics, Inc, H1 2016 23 Amyloidosis - Pipeline by Bellus Health Inc., H1 2016 24 Amyloidosis - Pipeline by Bsim2, H1 2016 25 Amyloidosis - Pipeline by Celgene Corporation, H1 2016 26 Amyloidosis - Pipeline by GlaxoSmithKline Plc, H1 2016 27 Amyloidosis - Pipeline by Neurimmune Holding AG, H1 2016 28 Amyloidosis - Pipeline by NeuroPhage Pharmaceuticals, Inc., H1 2016 29 Amyloidosis - Pipeline by Onyx Pharmaceuticals, Inc., H1 2016 30 Amyloidosis - Pipeline by Pfizer Inc., H1 2016 31 Amyloidosis - Pipeline by Prothena Corporation Plc, H1 2016 32 Amyloidosis - Pipeline by SOM Innovation Biotech SL, H1 2016 33 Amyloidosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 34 Assessment by Monotherapy Products, H1 2016 35 Assessment by Combination Products, H1 2016 36 Number of Products by Stage and Target, H1 2016 38 Number of Products by Stage and Mechanism of Action, H1 2016 40 Number of Products by Stage and Route of Administration, H1 2016 42 Number of Products by Stage and Molecule Type, H1 2016 44 Amyloidosis Therapeutics - Recent Pipeline Updates, H1 2016 91 Amyloidosis - Dormant Projects, H1 2016 128
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
